SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as community members digest the company's latest earnings report, with considerable focus on iPhone sales and forward guidance. Discussions revolve around the implications of revenue from China and the potential impact of AI advancements. Bullish sentiment appears to be fueled by the company's forecast for the holiday quarter.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the OG meme, emphasizing the power of grassroots movements over KOL-backed projects. Discussions revolve around community growth, with members expressing strong conviction and calling for a return to the original meme culture. The focus is on building a strong, unified community that can drive the project forward.

UP AND TO THE RIGHT

UPRIGHT CRYPTO is gaining attention as traders note its constructive chart patterns and consistent higher lows, suggesting a potential breakout. The community highlights strong accumulation, with some believing smart money is quietly loading up, anticipating a significant move. Discussions revolve around the idea that it's still early to get in, fostering a sense of opportunity for those who join now.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NLS Pharmaceutics Ltd

NLS Pharmaceutics is trending due to its completed merger with Kadimastem, forming NewCelX under the ticker NCEL, but some investors express concern over the reverse split and potential dilution. Community members are actively discussing the expected opening price, float size post-split, and potential for a squeeze, while also debating the merits of the merger and the new company's prospects. Trading halts and corporate actions are adding to the volatility and uncertainty surrounding the stock.

DLH Holdings Corp. engages in the provision of technology enabled business process outsourcing program management solutions and public health research and analytics. Its services and solutions include Defense and Veteran Health Solutions, Human Services and Solutions, Public Health and Life Sciences, and Infinibyte Cloud. The company was founded in 1969 and is headquartered in Atlanta, GA.

DLH Holdings Corp

DLHC is trending following news of a $90M contract with Veteran Affairs, sparking discussions about its low float and potential for significant upward movement. Community members are pointing to insider buying and net positive revenue as further bullish signals, with some speculating on a potential multi-day run. Analysts are weighing in with price target updates as well.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to a TD Cowen analyst reiterating a Buy rating with a $10 price target, citing the company's sales trajectory and strategic initiatives despite Medicare Part D coverage challenges for Xphozah. The community is discussing the potential for significant IBSRELA growth and the possibility of strategic acquisitions or mergers, fueled by Ardelyx's strong cash position. Heightened risks around cash flow and commercialization hurdles are also being weighed against the company's potential.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the tokenization of the legendary Satoshi Nakamoto, viewing it as the 'Bitcoin of memes' and a symbol of crypto culture. The community is anticipating increased visibility with upcoming events, including a feature on Mario Nawfal's Roundtable, driving excitement and discussion around its potential.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

MRNA is trending amid renewed buyout speculation, with chatter focusing on potential acquirers and valuation. The community is weighing the likelihood of a deal, considering the company's mRNA platform and pipeline, but some are skeptical. Potential infringement payouts are also being discussed as a factor in a buyout.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is gaining attention as traders discuss its potential for a breakout, citing healthy price action and accumulation patterns on its chart. Some community members are also excited about potential staking opportunities and projects launching on Solana. The recent buzz around Solana ETFs and integrations with major players like PayPal and Western Union also appear to be contributing to the positive sentiment.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending downwards amid discussions around a recent revenue miss, guidance cut, and dividend reduction aimed at debt repayment, leading to significant price declines. Community chatter revolves around whether the stock is oversold, if a turnaround is possible, and the potential impact of the dividend cut. Some traders are eyeing a short-term bounce while others express concern about the company's long-term prospects and debt.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SDRC The REE stuff is both good and bad.   
The negative is it really complicates the processing and geology and gets in the way of our absurdly high gold &amp; silver stockpile (~$1B in value) sitting on the ground waiting to be sold. 
The good news is the DoD is giving away lots of money to companies with high grade REE.  In Idaho alone Perpetua and US Criticals recieved big grants.  I think Sidney there&#39;s a very real possibility Sidney will get Gov funding for building out an REE Pilot Plant if our Assays come back good. 
 
We know we got some great stuff out of Knott Vein that can easily be processed into 60% TREO nnow we just need to find out where it came from and how much is there.  Share price if we get a grant will triple.   
Look at $IDR.  
Look at  $PPTA - Perpetua is worth $2.6B and they have yet to make a dollar in revenue.  I&#39;ve been long for years bc I know we&#39;re on the same or better path as these companies valued 10x SDRC, and Dan and Sean know it too.